The effect of ginseng on bile-pancreatic secretion in the rat. Increase in proteins and inhibition of total lipids and cholesterol secretion

Pharmacological Research

Volumn 45, Issue 4, 2002, Pages 349-353

  Abdel Salam, Omar M E ^a   Nada, Somaia A ^a   Arbid, Mahmoud S ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Bile secretion; Cholesterol; Ginseng; Lipids; Proteins; Rat

Indexed keywords

CHOLESTEROL; GINSENG EXTRACT; LIPID; PROTEIN; SODIUM CHLORIDE; URETHAN;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; BILE; BILE COMPOSITION; BILE DUCT; BILE FLOW; BILE SECRETION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GALLSTONE; GALLSTONE FORMATION; GINSENG; HERB; MALE; NONHUMAN; ODDI SPHINCTER; PANCREAS SECRETION; PRIORITY JOURNAL; RAT;

EID: 0036447341     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2002.0961     Document Type: Article

References (38)

1. Nocerino E, Amato M, Angelo A, Izzo U. The aphrodisiac and adaptogenic properties of ginseng. Fitoterapia 2000; 71: S1-S5.
2. Trease and Evans' Pharmacology. 13th Edn. Oxford: English Language Book Scociety/Bailliere Tindall, 1989: 490.
3. Brevoot P. The US botanical market: an overview. HerbalGram 1996; 36: 49-54.
4. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 1995; 18: 1373-5.
5. Jeong TC, Kim HJ, Park JI, Ha CS, Park JD, Kim SI, Roh JK. Protective effects of red ginseng saponins against carbon tetrachloride-induced hepatotoxicity in Sprague Dawley rats. Planta Med 1997; 63: 136-40.
6. Cui X, Sakaguchi T, Ishizuka D, Tsukada K, Hatakeyama K. Orally administered ginseng extract reduces serum total cholesterol and triglycerides that induce fatty liver in 66% hepatec-tomized rats. J Int Med Res 1998; 26: 181-7.
7. Cui X, Sakaguchi T, Shirai Y, Hatakeyama K. Orally administered Panax ginseng extract decreases platelet adhesiveness in 66% hepatectomized rats. Am J Chin Med 1999; 27: 251-6.
8. Yun TK, Choi SY. Non-organ specific cancer prevention of ginseng: A prospective study in Korea. Int J Epidemiol 1998; 27: 359-64.
9. Miller LG. Herbal medicinals. Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158: 2200-11.
10. Winslow LC, Kroll DJ. Herbs as medicines. Arch Intern Med 1998; 158: 2192-9.
11. Burwen SJ, Schmucker DL, Jones A. Subcellular and molecular mechanisms of bile secretion. Int Rev Cytol 1992; 135: 269-313.
12. Apstein MD, Russo AR. Amplicillin inhibits biliary cholesterol secretion. Dig Dis Sci 1985; 30: 253-6.
13. Nilsell K, Angelin B, Liljeqvist L, Einarsson K. Biliary lipid output and bile acid kinetics in cholesterol gallstone disease. Evidence for an increased hepatic secretion of cholesterol in Swedish patients. Gastroenterology 1985; 89: 287-93.
14. Hofmann AF. Pathogenesis of cholesterol gallstones. J Clin Gastroenterol 1988; 10(Suppl. 2): S1-11.
15. Richmond W. The development of an enzymatic technique for the assay of cholesterol in biological fluids. Scand J Clin Lab Invest 1972; 29: 25.
16. Bauer JD. Clinical Laboratory Methods. 9th Edn. St. Louis, Toronto, London: The C.V. Mosby Company, 1982: 552.
17. Welchselbaum CTE. An accurate and rapid method for the determination of proteins in small amounts of blood serum and plasma. Am J Clin Path 1946; 10: 40-5.
18. O'Hara M, Kiefer D, Farrell K, Kemper K. A review of 12 commonly used medicinal herbs. Arch Fam Med 1998; 7: 523-35.
19. Yamamoto M, Uemura T, Nakama S, Uemiya M, Kumagai A. Serum HDL-cholesterol-increasing and fatty liver-improving actions of Panax ginseng in high cholesterol diet-fed rats with clinical effect on hyperlipidemia in man. Am J Chin Med 1983; 11: 96-101.
20. Inoue M, Wu CZ, Dou DQ, Chen YJ, Ogihara Y. Lipoprotein lipase activation by red ginseng saponins in hyperlipidemia model animals. Phytomedicine 1999; 6: 257-65.
21. Kwon BM, Kim MK, Baek NI, Kim DS, Park JD, Kim YK, Lee HK, Kim SI. Acyl-CoA: Cholesterol acyltransferase inhibitory activity of ginseng sapogenins, produced from the ginseng saponins. Bioorg Med Chem Lett 1999; 9: 1375-8.
22. Rudney H, Sexton RC. Regulation of cholesterol biosynthesis. Annu Rev Nutr 1996; 6: 245-72.
23. Chang TY, Chang CCY, Cheng D. Acyl-coenzyme A:cholesterol acyltransferase. Annu Rev Biochem 1997; 66: 613-38.
24. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999; 159: 2647-58.
25. Tait N, Little JM. Fortnightly review: the treatment of gall stones. BMJ 1995; 311: 99-105.
26. Heuman DM, Wassef WY, Vlahcevic ZR. Gallstones. In: Schiff's Diseases of the Liver. Schiff ER, Sorrell MF, Maddrey WC, eds. Philadelphia: Lippincott-Raven Publishers, 1999: 631-4.
27. Turley SD, Dietschy JM. The metabolism and excretion of cholesterol by the liver. In: The Liver: Biology and Pathology. Arias IM, Jacoby WB, Popper H, Schachter D, eds. New York: Raven, 1988: 617-41.
28. Kern F. Effects of dietary cholesterol on cholesterol and bile acid homeostasis in patients with cholesterol gallstones. J Clin Invest 1994; 93: 1186-94.
29. Reihner E, Angelin B, Bjorkhem I, Einarsson K. Hepatic cholesterol metabolism in cholesterol gallstone disease. J Lipid Res 1991; 32: 469-75.
30. Gustafsson U, Sahlin S, Einarsson C. Biliary lipid composition in patients with cholesterol and pigment gallstones and gallstone-free subjects: Deoxycholic acid does not contribute to formation of cholesterol gallstones. Eur J Clin Invest 2000; 30: 1099-106.
31. Smith BF. Gallbladder mucin as a pronucleating agent for cholesterol monohydrate crystals in bile. Hepatology 1990; 12: 183S-6S.
32. Xu QW, Shaffer EA. Cisapride improves gallbladder contractility and bile lipid composition in an animal model of gallstone disease. Gastroenterology 1993; 105: 1184-191.
33. Chijiiwa K, Hirota I, Noshiro H. High vesicular cholesterol and protein in bile are associated with formation of cholesterol but not pigment gallstones. Dig Dis Sci 1993; 38: 161-6.
34. Smith JL, Roach PD, Wittenberg LN, Riottot M, Pillay SP, Nestel PJ, Nathanson LK. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 2000; 15: 871-9.
35. Tudyka J, Kratzer W, Janowitz P, Mason R, Wechsler JG. Combined bile acid therapy is more effective on biliary lipids and dissolution rates than monotherapy after gallstone lithotripsy. Am J Gastroenterol 1995; 90: 1942-8.
36. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatology 2001; 35: 134-46.
37. Miettinen TE, Kiviluoto T, Taavitsainen M, Vuoristo M, Miettinen TA. Cholesterol metabolism and serum and biliary non-cholesterol sterols in gallstone patients during simvastatin and ursodeoxycholic acid treatments. Hepatology 1998; 27: 649-55.
38. Qureshi AA, Abuirmeileh N, Din ZZ, Ahmad Y, Burger WC, Elson CE. Suppression of cholesterogenesis and reduction of LDL cholesterol by dietary ginseng and its fractions in chicken liver. Atherosclerosis 1983; 48: 81-94.